Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Bladder Cancer

  Free Subscription


1 Am J Cancer Res
2 Ann Surg Oncol
1 Anticancer Res
1 Appl Immunohistochem Mol Morphol
1 Arch Ital Urol Androl
1 Biochim Biophys Acta Mol Basis Dis
1 Bioeng Transl Med
1 Biomaterials
1 BMC Med Res Methodol
1 Br J Cancer
2 Cancer Cytopathol
1 Cancer Genomics Proteomics
1 Cancer Immunol Immunother
1 Cancer Immunol Res
2 Cancer Med
1 Cancer Res
1 Clin Genitourin Cancer
1 Comput Biol Med
1 Diagn Cytopathol
1 Discov Oncol
1 Enferm Infecc Microbiol Clin (Engl Ed)
1 Front Immunol
1 Future Oncol
1 Genes Genomics
1 Hinyokika Kiyo
1 IJU Case Rep
1 Int J Radiat Biol
1 J Cancer
1 J Cell Mol Med
1 J Chemother
1 J Int Med Res
1 JAMA Netw Open
1 Microbiome Res Rep
1 Minerva Urol Nephrol
1 Mol Carcinog
2 N Engl J Med
1 Nutr Cancer
2 Oncologist
1 Photodiagnosis Photodyn Ther
2 Radiographics
1 Sex Med
1 Toxicol Appl Pharmacol
1 Urol Oncol
3 Urology
2 World J Clin Oncol
1 World J Urol

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Cancer Res

  1. NAGATA Y, Goto T, Teramoto Y, Matsukawa T, et al
    Mineralocorticoid receptor signaling inhibits bladder cancer progression.
    Am J Cancer Res. 2024;14:696-708.
    PubMed         Abstract available

    Ann Surg Oncol

  2. DASON S, Lee CT
    Paradigm Shifting Research: Key Studies in Urologic Oncology.
    Ann Surg Oncol. 2024;31:2529-2537.
    PubMed         Abstract available

  3. MILOJEVIC B, Janicic A, Grozdic Milojevic I, Grubor N, et al
    Prognostic Impact of Preoperative Thrombocytosis on Recurrence-Free Survival in Patients with Upper Tract Urothelial Carcinoma.
    Ann Surg Oncol. 2024;31:2538-2544.
    PubMed         Abstract available

    Anticancer Res

  4. SHINDO T, Hashimoto K, Takahashi A, Miyamoto S, et al
    Comparison of Oncological Outcomes of Pembrolizumab as Second-line Therapy and Maintenance Avelumab Therapy in Advanced Urothelial Carcinoma After Platinum-based Chemotherapy.
    Anticancer Res. 2024;44:1271-1279.
    PubMed         Abstract available

    Appl Immunohistochem Mol Morphol

  5. KAPAGANTI VK, Purkait S, Nayak P, Biswas D, et al
    Diminution of Primary Cilia in the Stromal Cells at the Tumor-stromal Interface Correlates With an Aggressive Tumor Biology in the Urothelial Carcinoma of the Urinary Bladder.
    Appl Immunohistochem Mol Morphol. 2024;32:130-136.
    PubMed         Abstract available

    Arch Ital Urol Androl

    The relationship between income, health insurance, and employment status as prognostic indicators of bladder cancer: a survival analysis.
    Arch Ital Urol Androl. 2024 Mar 7:12305. doi: 10.4081/aiua.2024.12305.
    PubMed         Abstract available

    Biochim Biophys Acta Mol Basis Dis

  7. CHEN KC, Dhar T, Chen CR, Chen CY, et al
    Nicotinamide phosphoribosyltransferase modulates PD-L1 in bladder cancer and enhances immunotherapeutic sensitivity.
    Biochim Biophys Acta Mol Basis Dis. 2024 Feb 28:167106.
    PubMed         Abstract available

    Bioeng Transl Med

  8. XIONG Q, Liu T, Ying Y, Yu X, et al
    Establishment of bladder cancer spheroids and cultured in microfluidic platform for predicting drug response.
    Bioeng Transl Med. 2023;9:e10624.
    PubMed         Abstract available


  9. QI F, Bao Q, Hu P, Guo Y, et al
    Mild magnetic hyperthermia-activated immuno-responses for primary bladder cancer therapy.
    Biomaterials. 2024;307:122514.
    PubMed         Abstract available

    BMC Med Res Methodol

  10. ODURO MS
    A Bayesian Bernoulli-Exponential joint model for binary longitudinal outcomes and informative time with applications to bladder cancer recurrence data.
    BMC Med Res Methodol. 2024;24:54.
    PubMed         Abstract available

    Br J Cancer

  11. OUYANG Y, Zhong W, Xu P, Wang B, et al
    Tumor-associated neutrophils suppress CD8(+) T cell immunity in urothelial bladder carcinoma through the COX-2/PGE2/IDO1 Axis.
    Br J Cancer. 2024;130:880-891.
    PubMed         Abstract available

    Cancer Cytopathol

  12. ALHAMAR M, Al-Ahmadie HA, Feratovic R, Lin O, et al
    Sensitivity of urine cytology in detecting high-grade urothelial carcinoma in patients with neoplastic urinary bladder diverticula: A major cancer center experience.
    Cancer Cytopathol. 2024;132:144-151.
    PubMed         Abstract available

  13. LI JJX, Ng JKM, Tang CY, Chan BCH, et al
    Urine cytology in the detection of renal cell carcinomas - a territory-wide multi-institutional retrospective review of more than 2 decades.
    Cancer Cytopathol. 2024;132:186-192.
    PubMed         Abstract available

    Cancer Genomics Proteomics

  14. OKUDA Y, Kato T, Fujita K, Fushimi H, et al
    Association of Androgen Receptor and PD-L1 Expression in Upper Urinary Tract Urothelial Carcinoma.
    Cancer Genomics Proteomics. 2024;21:137-143.
    PubMed         Abstract available

    Cancer Immunol Immunother

  15. LI B, Jin K, Liu Z, Su X, et al
    Integrating molecular subtype and CD8(+) T cells infiltration to predict treatment response and survival in muscle-invasive bladder cancer.
    Cancer Immunol Immunother. 2024;73:66.
    PubMed         Abstract available

    Cancer Immunol Res

  16. ZHANG H, Lee S, Muthakana RR, Lu B, et al
    Intragenic Rearrangement Burden Associates with Immune Cell Infiltration and Response to Immune Checkpoint Blockade in Cancer.
    Cancer Immunol Res. 2024;12:287-295.
    PubMed         Abstract available

    Cancer Med

  17. BARCENA PGQ, Aprikian AG, Dragomir A
    Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.
    Cancer Med. 2024;13:e6922.
    PubMed         Abstract available

  18. LIU G, Jin K, Liu Z, Su X, et al
    POLQ identifies a better response subset to immunotherapy in muscle-invasive bladder cancer with high PD-L1.
    Cancer Med. 2024;13:e6962.
    PubMed         Abstract available

    Cancer Res

  19. HOSNI S, Kilian V, Klumper N, Gabbia D, et al
    Adipocyte Precursor-Derived NRG1 Promotes Resistance to FGFR Inhibition in Urothelial Carcinoma.
    Cancer Res. 2024;84:725-740.
    PubMed         Abstract available

    Clin Genitourin Cancer

  20. SZCZESNIEWSKI JJ, Marquez-Sanchez MT, Padilla-Fernandez B, Llanes-Gonzalez L, et al
    Recurrent Bacteriuria as a Prognosis Marker in the Adjuvant Treatment of Non-Muscle Invasive Bladder Cancer.
    Clin Genitourin Cancer. 2024;22:102048.
    PubMed         Abstract available

    Comput Biol Med

  21. HAO S, Shen L, Liu P, Yong Q, et al
    Development of a prognostic model for muscle-invasive bladder cancer using glutamine metabolism.
    Comput Biol Med. 2024;171:108223.
    PubMed         Abstract available

    Diagn Cytopathol

  22. KANNAN N, Gochhait D, Ramanitharan M, Siddaraju N, et al
    A comparison between conventional and the Paris systems of reporting urinary cytopathology with a literature update.
    Diagn Cytopathol. 2024;52:187-199.
    PubMed         Abstract available

    Discov Oncol

  23. KONG YL, Wang HD, Gao M, Rong SZ, et al
    LncRNA XIST promotes bladder cancer progression by modulating miR-129-5p/TNFSF10 axis.
    Discov Oncol. 2024;15:65.
    PubMed         Abstract available

    Enferm Infecc Microbiol Clin (Engl Ed)

  24. RAICES FRANCISCO N, Suarez Gil R, Ayuso Garcia B, Romay Lema E, et al
    BCGitis with aortoiliac aneurysm involvement: Report of two cases and review of the literature.
    Enferm Infecc Microbiol Clin (Engl Ed). 2024;42:152-157.
    PubMed         Abstract available

    Front Immunol

  25. HUANG Y, Liao C, Shen Z, Zou Y, et al
    A bibliometric insight into neoadjuvant chemotherapy in bladder cancer: trends, collaborations, and future avenues.
    Front Immunol. 2024;15:1297542.
    PubMed         Abstract available

    Future Oncol

  26. LORIOT Y, O'Hagan A, Siefker-Radtke AO
    Plain language summary of erdafitinib in locally advanced or metastatic urothelial carcinoma: a phase 2 study with long-term follow-up.
    Future Oncol. 2024;20:231-243.
    PubMed         Abstract available

    Genes Genomics

  27. LIU Y, Zou SH, Gao X
    Bioinformatics analysis and experimental validation reveal that CDC20 overexpression promotes bladder cancer progression and potential underlying mechanisms.
    Genes Genomics. 2024 Mar 4. doi: 10.1007/s13258-024-01505.
    PubMed         Abstract available

    Hinyokika Kiyo

  28. OSHIRO H, Shimizu Y, Nakayasu R, Yamaguchi R, et al
    [Bladder Cancer Detected Incidentally by Cystoscopy before Radical Prostatectomy].
    Hinyokika Kiyo. 2024;70:39-43.
    PubMed         Abstract available

    IJU Case Rep

  29. MITANI K, Tsuboi I, Tanaka G, Yosioka S, et al
    Metastatic small cell bladder cancer treated with sequential systemic therapy including pembrolizumab and amrubicin: A case report.
    IJU Case Rep. 2023;7:127-130.
    PubMed         Abstract available

    Int J Radiat Biol

  30. WANG Q, Zhang R, He Y, Mao G, et al
    Taraxasterol enhanced bladder cancer cells radiosensitivity via inhibiting the COX-2/PGE2/JAK2/STAT3/MMP pathway.
    Int J Radiat Biol. 2024 Mar 5:1-11. doi: 10.1080/09553002.2024.2324475.
    PubMed         Abstract available

    J Cancer

  31. WEI H, Cheng X, Wang G, Li Z, et al
    Causal association of smoking, blood lipids, and bladder cancer: Insights from a multivariable and mediation mendelian randomization investigation.
    J Cancer. 2024;15:1929-1939.
    PubMed         Abstract available

    J Cell Mol Med

  32. FU Y, Sun S, Shi D, Bi J, et al
    Construction of endothelial cell signatures for predicting the diagnosis, prognosis and immunotherapy response of bladder cancer via machine learning.
    J Cell Mol Med. 2024;28:e18155.
    PubMed         Abstract available

    J Chemother

  33. ABOU CHAKRA M, Moussa M, O'Donnell MA
    Intravesical sequential gemcitabine/docetaxel for non-muscle invasive bladder cancer: tips and tricks for better efficacy and tolerability.
    J Chemother. 2024 Mar 4:1-4. doi: 10.1080/1120009X.2024.2325765.

    J Int Med Res

  34. HUANG XL, Sun Y, Wen P, Pan JC, et al
    The potential mechanism of ursolic acid in the treatment of bladder cancer based on network pharmacology and molecular docking.
    J Int Med Res. 2024;52:3000605241234006.
    PubMed         Abstract available

    JAMA Netw Open

  35. MAIORANO BA, Di Maio M, Cerbone L, Maiello E, et al
    Significance of PD-L1 in Metastatic Urothelial Carcinoma Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
    JAMA Netw Open. 2024;7:e241215.
    PubMed         Abstract available

    Microbiome Res Rep

  36. PENG Z, Zhuang J, Shen B
    The role of microbiota in tumorigenesis, progression and treatment of bladder cancer.
    Microbiome Res Rep. 2023;3:5.
    PubMed         Abstract available

    Minerva Urol Nephrol

  37. BASILE G, Gallioli A, Martini A, Verri P, et al
    Oncologic surveillance intensity after endoscopic treatment of upper tract urothelial carcinoma.
    Minerva Urol Nephrol. 2024;76:88-96.
    PubMed         Abstract available

    Mol Carcinog

  38. ZHANG Q, Wang L, Yu L, Yu Q, et al
    Tectoridin inhibits the growth of bladder cancer by regulating PI3K/MAPK pathway through RAB27B.
    Mol Carcinog. 2024 Mar 5. doi: 10.1002/mc.23712.
    PubMed         Abstract available

    N Engl J Med

    Enfortumab Vedotin and Pembrolizumab - A New Perspective on Urothelial Cancer.
    N Engl J Med. 2024;390:944-946.

  40. POWLES T, Valderrama BP, Gupta S, Bedke J, et al
    Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
    N Engl J Med. 2024;390:875-888.
    PubMed         Abstract available

    Nutr Cancer

  41. CHEN YT, Tang QY, Zhang YX, Wang SZ, et al
    An Atlas of Dietary Intakes and Medication Uses on Risk of Bladder Cancer: A Wide-Angle Mendelian Randomization Analysis.
    Nutr Cancer. 2024 Mar 5:1-10. doi: 10.1080/01635581.2024.2324504.
    PubMed         Abstract available


  42. MUQUITH M, Hsiehchen D
    Landscape and Saturation Analysis of Mutations Associated With Race in Cancer Genomes by Clinical Sequencing.
    Oncologist. 2024;29:219-226.
    PubMed         Abstract available

  43. GUPTA S, Costantino H, Ike C, Gupta S, et al
    Evaluating Oncologists' Practice Patterns and Decision-Making in Locally Advanced or Metastatic Urothelial Carcinoma: The US Physician PARADIGM Study.
    Oncologist. 2024;29:244-253.
    PubMed         Abstract available

    Photodiagnosis Photodyn Ther

  44. XU Q, Li T, Lin J, Wu X, et al
    Label-free screening of common urinary system tumors from blood plasma based on surface-enhanced Raman spectroscopy.
    Photodiagnosis Photodyn Ther. 2024;45:103900.
    PubMed         Abstract available


    Invited Commentary: VI-RADS and Routing Patient Care at the Muscularis Propria.
    Radiographics. 2024;44:e230234.

  46. FAVERO PRIETTO DOS SANTOS J, Ghezzi CLA, Pedrollo IM, Cruz IR, et al
    Practical Guide to VI-RADS: MRI Protocols, Lesion Characterization, and Pitfalls.
    Radiographics. 2024;44:e230149.
    PubMed         Abstract available

    Sex Med

  47. NOLTING J, Nitzsche R, Kiss B, Hakenberg OW, et al
    Prospective evaluation of sexual health following radical cystectomy due to bladder cancer.
    Sex Med. 2024;12:qfae005.
    PubMed         Abstract available

    Toxicol Appl Pharmacol

  48. CHEN J, Fan S, Guo J, Yang J, et al
    Discovery of anticancer function of Febrifugine: Inhibition of cell proliferation, induction of apoptosis and suppression steroid synthesis in bladder cancer cells.
    Toxicol Appl Pharmacol. 2024;484:116878.
    PubMed         Abstract available

    Urol Oncol

  49. COOKE I, Abou Heidar N, Mahmood AW, Ahmad A, et al
    The role of neoadjuvant chemotherapy for patients with variant histology muscle invasive bladder cancer undergoing robotic cystectomy: Data from the International Robotic Cystectomy Consortium.
    Urol Oncol. 2024 Feb 29:S1078-1439(24)00002.
    PubMed         Abstract available


  50. LIBLIK K, Queen JC, Touma NJ
    Immune Checkpoint Inhibitors for Kidney and Bladder Cancer: Adrenotoxic Consequences.
    Urology. 2024 Feb 29:S0090-4295(24)00129-8. doi: 10.1016/j.urology.2024.

  51. LEPOR H, Wiegand L, Patel K, Du W, et al
    A Randomized Clinical Trial Evaluating Indigo Carmine as a Visualization Aid for Evaluating Ureteral Patency.
    Urology. 2024;184:105-111.
    PubMed         Abstract available

  52. WEISS K, Abimbola O, Miller K, Kim WY, et al
    Near Complete Response to Platinum-based Systemic Chemotherapy in High-risk Upper Tract Urothelial Carcinoma With an ERBB2 Gene Mutation: A Case Report.
    Urology. 2024;184:75-78.
    PubMed         Abstract available

    World J Clin Oncol

  53. ZHOU SQ, Luo LX
    TM9SF1 is implicated in promoting the proliferation and invasion of bladder cancer cells.
    World J Clin Oncol. 2024;15:175-177.
    PubMed         Abstract available

  54. WEI L, Wang SS, Huang ZG, He RQ, et al
    TM9SF1 promotes bladder cancer cell growth and infiltration.
    World J Clin Oncol. 2024;15:302-316.
    PubMed         Abstract available

    World J Urol

  55. LI M, Nandurkar R, Toniolo J, Davis ID, et al
    A phase 2 pilot study of water irrigation after transurethral resection of bladder tumor (WATIP) demonstrating safety, feasibility and activity.
    World J Urol. 2024;42:115.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Bladder Cancer is free of charge.